US Patent Issued to Principia Biopharma on June 24 for "Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl) pyrazolo[3,4-d pyrimidin-1-ylpiperidine-1-carbonyl-4-methyl-4-[4-(oxetan-3-yl) piperazin-1-ylpent-2-enenitrile" (British, American Inventors)

ALEXANDRIA, Va., June 25 -- United States Patent no. 12,336,999, issued on June 24, was assigned to Principia Biopharma Inc. (Bridgewater, N.J.).

"Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl) pyrazolo[3,4-d pyrimidin-1-ylpiperidine-1-carbonyl-4-methyl-4-[4-(oxetan-3-yl) piperazin-1-ylpent-2-enenitrile" was invented by Abu J. Ferdous (Belmont, Calif.), Mohammad R. Masjedizadeh (San Jose, Calif.) and Wu Lin (Nottingham, Great Britain).

According to the abstract* released by the U.S. Patent & Trademark Office: "Modified release formulations, such as solid oral dosage forms comprising a core composition comprising Compound (I) and/or a pharmaceutically acceptable salt thereof; a sub-coating layer coating the co...